We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.00 | 0.24% | 1,655.00 | 1,655.00 | 1,655.50 | 1,661.50 | 1,652.00 | 1,656.50 | 169,134 | 08:32:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.79 | 67.97B |
Date | Subject | Author | Discuss |
---|---|---|---|
03/5/2019 08:32 | The merger and subsequent divestment of the Consumer Healthcare business will herald a new era for the company …. ;0) | tradermichael | |
03/5/2019 08:28 | Price below what it was 22 years ago, it's a income stock and not a growth share, it's like having a corporate bond but with more risk. Wonder if it will be this price in 22 years time. | montyhedge | |
02/5/2019 15:55 | So now it's all up to the rats,the ball is in their court. | abdullla | |
02/5/2019 14:30 | Yeah thats exactly what we are wishing for, a plague, that only gsk have the cure for and we all cash out with huge profits at 50 quid a share bwahaha | porsche1945 | |
02/5/2019 13:30 | All agreed,just testing. | abdullla | |
02/5/2019 11:57 | Of course without shareholders no life saving drugs, no pharma companies. | montyhedge | |
02/5/2019 11:55 | GSK's 150 year history has brought improved health to and saved the lives of millions of people worldwide, enabling them to "Do more, feel better live longer". As shareholders, supporting this quest, its never unreasonable to expect an investment return. | tradermichael | |
02/5/2019 11:13 | No investor has to wish for nasty illnesses.A rising global population and increased longevity pretty much assures rising demand for medication. | steeplejack | |
02/5/2019 07:56 | Are the investors wishing a world full of nasty diseases so they can see their pharma share price shooting up and up,sad very sad indeed. | abdullla | |
02/5/2019 07:53 | 1997 average shareprice 1581p, 22 years later 1550p.Wow that's some growth, lol.Sogosit, still got Micro Focus, glad I sold 2540p. | montyhedge | |
02/5/2019 07:05 | Usual carp from monty who cannot subtract 25 from 2018 and look up what that year's share price was. Hey, monty, best trader on advfn who can't read a share price chart! Lol! | sogoesit | |
02/5/2019 07:01 | Alzheimer's can be caught .... It's a transmissible disease Alzheimer's disease is a 'double-prion disorder' Self-propagating amyloid and tau prions found in post-mortem brain samples, with highest levels in patients who died young May 1, 2019 “I believe this shows beyond a shadow of a doubt that amyloid beta and tau are both prions, and that Alzheimer’s disease is a double-prion disorder in which these two rogue proteins together destroy the brain,” said Stanley Prusiner, MD, the study’s senior author and director of the UCSF Institute for Neurodegenerative Diseases, part of the UCSF Weill Institute for Neurosciences. “The fact that prion levels also appear linked to patient longevity should change how we think about the way forward for developing treatments for the disease. Over the past decade, laboratory studies at UCSF and elsewhere have begun to show that amyloid plaques and tau tangles from diseased brains can infect healthy brain tissue much like PrP, but considerably more slowly. | buywell3 | |
01/5/2019 19:55 | Transcript and slides for anyone so disposed... GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2019 Results - Earnings Call Transcript GlaxoSmithKline plc 2019 Q1 - Results - Earnings Call Slides | crossing_the_rubicon | |
01/5/2019 19:20 | Oh really, that's ok for you and me, but a lot of investors just buy and hold.GSK shareprice is below what they where 25 years ago. More a bond than a share. | montyhedge | |
01/5/2019 17:41 | Does this represent the share movement today; very little movement pre results; very soon after results a big leap as some read the good improvement in income due to new products in this quarter, only to recognise later that this improvement is not sufficient to outweigh the loss due to Advair across the year as a whole? Or is there a better explanation? | jadeticl3 | |
01/5/2019 15:54 | Yes - Monty, that's why you trade them on the peaks and troughs, routinely. Then always HOLD in time for the regular dividend. Compound the proceeds and increase your holdings annually. | tradermichael | |
01/5/2019 15:50 | If you have 40000 shares and you buy and sell some or all of them when the share price spikes either way then you could make a capital gains of £100,000,timing and luck will have to be your co-pilots . | abdullla | |
01/5/2019 14:58 | Dividend will never be increased been the same for years, just like holding a bond not a ord share. The whole point holding shares is for dividend growth and capital gain. GSK shareprice the same has it was 25 years ago, what growth. Poor show. | montyhedge | |
01/5/2019 13:52 | Just cannot seem to sort earning cash, earnings per share poor, always the same, hover around this until ex div then back to 15.20, time to buy in and sell again on way to next ex div, good trading share but thats all, useless for capital growth and if you want income there are funds with higher yields and lower stock specific risks, if she decides to buy another bio tech for billions this will tank again and put div at risk, its still being paid from debt. I know you " lifers " are waiting for the March to 1900 but its never gonna happen. | porsche1945 | |
01/5/2019 13:35 | Great figs imo! spud | spud | |
01/5/2019 13:28 | Thanks TM,you are right,euphoria was at the open for most investors when the share price jumped 20p at the opening bell,now things are balancing out for a brighter future,imo | abdullla | |
01/5/2019 12:49 | abdullla: The reduction primarily reflected the adverse phasing of payments for returns and rebates, as well as the initial step-down impact from Advair generic competition and an increase in trade receivables as a result of strong sales in the quarter, partly offset by improved operating profits and lower contingent consideration payments compared with Q1 2018 which included a milestone payment to Novartis. | tradermichael | |
01/5/2019 12:39 | There's those who are reading between the lines,abdullla just on the first paragraph hence the euphoria,sorry | abdullla | |
01/5/2019 12:35 | Market thinking too. ;) | alphorn | |
01/5/2019 12:32 | Make your mind up, abdulla. | keyno |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions